Style | Citing Format |
---|---|
MLA | Saeednejad Zanjani L, et al.. "Cytoplasmic Expression of Cd133 Stemness Marker Is Associated With Tumor Aggressiveness in Clear Cell Renal Cell Carcinoma." Experimental and Molecular Pathology, vol. 103, no. 2, 2017, pp. 218-228. |
APA | Saeednejad Zanjani L, Madjd Z, Abolhasani M, Andersson Y, Rasti A, Shariftabrizi A, Asgari M (2017). Cytoplasmic Expression of Cd133 Stemness Marker Is Associated With Tumor Aggressiveness in Clear Cell Renal Cell Carcinoma. Experimental and Molecular Pathology, 103(2), 218-228. |
Chicago | Saeednejad Zanjani L, Madjd Z, Abolhasani M, Andersson Y, Rasti A, Shariftabrizi A, Asgari M. "Cytoplasmic Expression of Cd133 Stemness Marker Is Associated With Tumor Aggressiveness in Clear Cell Renal Cell Carcinoma." Experimental and Molecular Pathology 103, no. 2 (2017): 218-228. |
Harvard | Saeednejad Zanjani L et al. (2017) 'Cytoplasmic Expression of Cd133 Stemness Marker Is Associated With Tumor Aggressiveness in Clear Cell Renal Cell Carcinoma', Experimental and Molecular Pathology, 103(2), pp. 218-228. |
Vancouver | Saeednejad Zanjani L, Madjd Z, Abolhasani M, Andersson Y, Rasti A, Shariftabrizi A, et al.. Cytoplasmic Expression of Cd133 Stemness Marker Is Associated With Tumor Aggressiveness in Clear Cell Renal Cell Carcinoma. Experimental and Molecular Pathology. 2017;103(2):218-228. |
BibTex | @article{ author = {Saeednejad Zanjani L and Madjd Z and Abolhasani M and Andersson Y and Rasti A and Shariftabrizi A and Asgari M}, title = {Cytoplasmic Expression of Cd133 Stemness Marker Is Associated With Tumor Aggressiveness in Clear Cell Renal Cell Carcinoma}, journal = {Experimental and Molecular Pathology}, volume = {103}, number = {2}, pages = {218-228}, year = {2017} } |
RIS | TY - JOUR AU - Saeednejad Zanjani L AU - Madjd Z AU - Abolhasani M AU - Andersson Y AU - Rasti A AU - Shariftabrizi A AU - Asgari M TI - Cytoplasmic Expression of Cd133 Stemness Marker Is Associated With Tumor Aggressiveness in Clear Cell Renal Cell Carcinoma JO - Experimental and Molecular Pathology VL - 103 IS - 2 SP - 218 EP - 228 PY - 2017 ER - |